Arun Sreekumar

Dr. Arun Sreekumar


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ATAtsushi Terunuma
Atsushi Terunuma
Nagireddy PutluriNagireddy Putluri
Nagireddy Putluri
PMPrachi Mishra
Prachi Mishra
Ewy MathéEwy Mathé
Ewy Mathé
TDTiffany H. Dorsey
Tiffany H. Dorsey
Stefan AmbsStefan Ambs
Stefan Ambs
Metabolic profiling of cancer cells has recently been established as a promising tool for the development of therapies and identification of cancer biomarkers. Here we characterized the metabolomic profile of human breast tumors and uncovered intrinsic metabolite signatures in these tumors using an untargeted discovery approach and validation of key metabolites. The oncometabolite 2-hydroxyglutarate (2HG) accumulated at high levels in a subset of tumors and human breast cancer cell lines. We discovered an association between increased 2HG levels and MYC pathway activation in breast cancer, and further corroborated this relationship using MYC overexpression and knockdown in human mammary epithelial and breast cancer cells. Further analyses revealed globally increased DNA methylation in 2HG-high tumors and identified a tumor subtype with high tissue 2HG and a distinct DNA methylation pattern that was associated with poor prognosis and occurred with higher frequency in African-American patients. Tumors of this subtype had a stem cell–like transcriptional signature and tended to overexpress glutaminase, suggestive of a functional relationship between glutamine and 2HG metabolism in breast cancer. Accordingly, 13C-labeled glutamine was incorporated into 2HG in cells with aberrant 2HG accumulation, whereas pharmacologic and siRNA-mediated glutaminase inhibition reduced 2HG levels. Our findings implicate 2HG as a candidate breast cancer oncometabolite associated with MYC activation and poor prognosis.

1 May 2014 in Neoplasia
Verified
Journal Article
Open access
Nagireddy PutluriNagireddy Putluri
Nagireddy Putluri
SMSuman Maity
Suman Maity
RKRamakrishna Kommagani
Ramakrishna Kommagani
CCChad J. Creighton
Chad J. Creighton
VPVasanta Putluri
Vasanta Putluri
ASArun Sreekumar
Arun Sreekumar
Breast cancer (BCa) molecular subtypes include luminal A, luminal B, normal-like, HER-2-enriched, and basal-like tumors, among which luminal B and basal-like cancers are highly aggressive. Biochemical pathways associated with patient survival or treatment response in these more aggressive subtypes are not well understood. With the limited availability of pathologically verified clinical specimens, cell line models are routinely used for pathway-centric studies. We measured the metabolome of luminal and basal-like BCa cell lines using mass spectrometry, linked metabolites to biochemical pathways using Gene Set Analysis, and developed a novel rank-based method to select pathways on the basis of their enrichment in patient-derived omics data sets and prognostic relevance. Key mediators of the pathway were then characterized for their role in disease progression. Pyrimidine metabolism was altered in luminal versus basal BCa, whereas the combined expression of its associated genes or expression of one key gene, ribonucleotide reductase subunit M2 (RRM2) alone, associated significantly with decreased survival across all BCa subtypes, as well as in luminal patients resistant to tamoxifen. Increased RRM2 expression in tamoxifen-resistant patients was verified using tissue microarrays, whereas the metabolic products of RRM2 were higher in tamoxifen-resistant cells and in xenograft tumors. Both genetic and pharmacological inhibition of this key enzyme in tamoxifen-resistant cells significantly decreased proliferation, reduced expression of cell cycle genes, and sensitized the cells to tamoxifen treatment. Our study suggests for evaluating RRM2-associated metabolites as noninvasive markers for tamoxifen resistance and its pharmacological inhibition as a novel approach to overcome tamoxifen resistance in BCa.

1 August 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
SBSalil Kumar Bhowmik
Salil Kumar Bhowmik
EREsmeralda Ramirez-Peña
Esmeralda Ramirez-Peña
JAJames Michael Arnold
James Michael Arnold
VPVasanta Putluri
Vasanta Putluri
NSNATHALIE SPHYRIS
NATHALIE SPHYRIS
SMSendurai Mani
Sendurai Mani
EMT-Induced Metabolite Signature Identifies Poor Clinical Outcome

13 July 2018 in Metabolites
Verified
Journal Article
Open access
PDF file
PPPreeti Purwaha
Preeti Purwaha
FGFranklin Gu
Franklin Gu
DPDanthasinghe Waduge Badrajee Piyarathna
Danthasinghe Waduge Badrajee Piyarathna
TRTheckelnaycke Rajendiran
Theckelnaycke Rajendiran
ARAnindita Ravindran
Anindita Ravindran
ASArun Sreekumar
Arun Sreekumar
The reprogramming of lipid metabolism is a hallmark of many cancers that has been shown to promote breast cancer progression. While several lipid signatures associated with breast cancer aggressiveness have been identified, a comprehensive lipidomic analysis specifically targeting the triple-negative subtype of breast cancer (TNBC) may be required to identify novel biomarkers and therapeutic targets for this most aggressive subtype of breast cancer that still lacks effective therapies. In this current study, our global LC-MS-based lipidomics platform was able to measure 684 named lipids across 15 lipid classes in 70 TNBC tumors. Multivariate survival analysis found that higher levels of sphingomyelins were significantly associated with better disease-free survival in TNBC patients. Furthermore, analysis of publicly available gene expression datasets identified that decreased production of ceramides and increased accumulation of sphingoid base intermediates by metabolic enzymes were associated with better survival outcomes in TNBC patients. Our LC-MS lipidomics profiling of TNBC tumors has, for the first time, identified sphingomyelins as a potential prognostic marker and implicated enzymes involved in sphingolipid metabolism as candidate therapeutic targets that warrant further investigation.

1 August 2015 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
SLStacy M. Lloyd
Stacy M. Lloyd
JAJames Arnold
James Arnold
ASArun Sreekumar
Arun Sreekumar

22 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
EREsmeralda Ramirez-Peña
Esmeralda Ramirez-Peña
JAJames Arnold
James Arnold
VSVinita Shivakumar
Vinita Shivakumar
RJRobiya Joseph
Robiya Joseph
GVGeraldine Vidhya Vijay
Geraldine Vidhya Vijay
SMSendurai Mani
Sendurai Mani
Identifying bioenergetics that facilitate the epithelial to mesenchymal transition (EMT) in breast cancer cells may uncover targets to treat incurable metastatic disease. Metastasis is the number one cause of cancer-related deaths; therefore, it is urgent to identify new treatment strategies to prevent the initiation of metastasis. To characterize the bioenergetics of EMT, we compared metabolic activities and gene expression in cells induced to differentiate into the mesenchymal state with their epithelial counterparts. We found that levels of GLS2, which encodes a glutaminase, are inversely associated with EMT. GLS2 down-regulation was correlated with reduced mitochondrial activity and glutamine independence even in low-glucose conditions. Restoration of GLS2 expression in GLS2-negative breast cancer cells rescued mitochondrial activity, enhanced glutamine utilization, and inhibited stem-cell properties. Additionally, inhibition of expression of the transcription factor FOXC2, a critical regulator of EMT in GLS2-negative cells, restored GLS2 expression and glutamine utilization. Furthermore, in breast cancer patients, high GLS2 expression is associated with improved survival. These findings suggest that epithelial cancer cells rely on glutamine and that cells induced to undergo EMT become glutamine independent. Moreover, the inhibition of EMT leads to a GLS2-directed metabolic shift in mesenchymal cancer cells, which may make these cells susceptible to chemotherapies.